Search

KR-20260062968-A - COMPOSITIONS COMPRISING POLAR LIPIDS FOR MAINTAINING OR INCREASING MOBILITY AND VITALITY

KR20260062968AKR 20260062968 AKR20260062968 AKR 20260062968AKR-20260062968-A

Abstract

The present invention provides a method for maintaining or increasing mobility and/or vitality, particularly for middle-aged women who lead a sedentary lifestyle, by administering a composition comprising one or more polar lipids, such as a milk fat globule membrane, whey, and other dairy products.

Inventors

  • 노리스 카르멘 사라
  • 패닝 아론 캘빈
  • 건 캐롤라인 앤
  • 스콜럼 린다 메이
  • 맥기본 앨러스테어 케니스 휴

Assignees

  • 폰테라 코-오퍼레이티브 그룹 리미티드

Dates

Publication Date
20260507
Application Date
20191220
Priority Date
20190321

Claims (20)

  1. A composition comprising a lipid-lowering membrane material comprising one or more polar lipids for maintaining or increasing motility and/or vitality in a human subject, (a) Maintaining or increasing performance includes the following: (i) after administering the composition daily for a period of at least 3 or 4 months, an increase in at least 0.65 cm in rebound jump height and/or an increase in rebound jump power relative to the rebound weight ratio by at least 6.75%, comprising the subject performing exercise at least 2 days per week compared to the subject's performance before starting daily administration of the composition; and/or (ii) Maintain or increase lean body muscle mass and/or maintain or decrease body fat mass; and (b) Maintaining or increasing vitality includes the following: (i) increase in daily physical activity and decrease in sedentary time of the subject; or (ii) A composition in which, after administering the composition daily for a period of at least 3 or 4 months, the subject exercises at least 2 days per week compared to the subject’s sedentary and/or light-intensity physical activity time prior to the start of daily administration of the composition, a reduction in sedentary activity time of at least 7 minutes per day and/or an increase in light-intensity physical activity time of at least 3 minutes per day.
  2. In paragraph 1, (a) an increase in rebound jump height of at least 0.7, 0.8, 0.9 or 1 cm or 0.65 to 4 cm; and/or (b) A composition having an increase in rebound jumping power for at least 6.8, 6.9, 7, or 7.2% rebound weight ratio when the subject exercises at least 2 days per week compared to the subject's performance before the daily administration of the composition began, after administering the composition daily for a period of at least 3 or 4 months.
  3. In paragraph 1, A composition having an increase in trunk lean muscle mass of at least 0.25, 0.3, 0.4, or 0.5 kg or 0.25 to 1 kg when the subject exercises at least 2 days per week compared to the trunk lean muscle mass prior to the start of daily administration of the composition, after administering the composition daily for a period of at least 3 or 4 months.
  4. In paragraph 1, (a) Reduction of sedentary time by at least 10, 15, or 20 minutes per day; and/or (b) a composition in which, after administering the composition daily for a period of at least 3 or 4 months, the subject exercises at least 2 days per week compared to the subject’s sedentary and/or light-intensity physical activity time prior to the start of daily administration of the composition, the subject’s light-intensity physical activity time increases by at least 5, 7, or 10 minutes per day.
  5. In paragraph 1, Maintaining or increasing vitality includes the following: (a) an increase in the time of moderate to high-intensity physical activity for at least 1,25, 1,5, 2,5, 3, or 5 minutes per day; and/or (b) a composition in which, after administering the composition daily for a period of at least 3 or 4 months, the subject exercises at least 2 days per week, and the subject’s score on a subjective vitality scale increases by at least 2.6, 2.75, 3, or 3.25 compared to the subject’s time and/or score of moderate to high intensity physical activity prior to the start of daily administration of the composition.
  6. In paragraph 1, The above-mentioned subject is a composition aged 45 to 75 years.
  7. In paragraph 1, The composition is formulated to provide at least 200 mg of one or more polar lipids per day.
  8. In paragraph 1, The present composition is a nutritional composition.
  9. In paragraph 1, The present composition is a beverage, bar, gel, shot, fermented milk, UHT milk, yogurt, custard, ice cream, cheese, chips, chocolate, multi-layered bite, supplement, tablet, capsule, confectionery, or milk powder.
  10. In Paragraph 9, A composition in which the beverage is fruit juice, sports drink, or milk drink.
  11. In paragraph 1, The composition is a pharmaceutical composition comprising a pharmaceutically acceptable adjuvant or carrier.
  12. In paragraph 1, The present composition is (a) At least 5 g of protein per day, (b) 0.1 to 10 g of lipids per day, (c) At least 0.75 g of calcium per day, (d) At least 7.5 μg of vitamin D per day, or (e) Any combination of any two or more of (a) through (d) A composition formulated to provide one or more of the above, or administered separately, simultaneously, or sequentially.
  13. In paragraph 1, The present composition is (a) At least 5 g of protein per day, (b) 0.1 to 10 g of lipids per day, (c) At least 0.75 g of calcium per day, and (d) At least 7.5 μg of vitamin D per day A composition formulated to provide one or more of the above, or administered separately, simultaneously, or sequentially.
  14. In paragraph 1, The present composition comprises at least 0.3 g of one or more polar lipids per 100 g of the composition on a dry matter basis.
  15. In paragraph 1, This composition is based on dry matter. (a) at least 5 wt% protein, (b) 0.01 to 20 weight% lipids, (c) At least 1 wt% calcium, (d) at least 10 μg of vitamin D per 100 g of composition, or (e) A composition comprising any combination of any two or more of (a) to (d).
  16. In paragraph 1, This composition is based on dry matter. (a) at least 5 wt% protein, (b) 0.01 to 20 weight% lipids, (c) at least 1 wt% calcium, and (d) A composition comprising at least 10 μg of vitamin D per 100 g of composition.
  17. In paragraph 1, A composition comprising one or more polar lipids, wherein the polar lipids are derived from non-human mammalian milk.
  18. In paragraph 1, A composition comprising one or more polar lipids, comprising one or more phospholipids, one or more gangliosides, one or more ceramides, one or more cerebrosides, one or more sphingolipids, or any combination of any two or more of these.
  19. In Paragraph 18, A composition comprising one or more gangliosides, including GD3, GM3, or a combination thereof.
  20. In Paragraph 18, A composition comprising one or more phospholipids, wherein one or more phosphatidylcholine, one or more phosphatidylinositol, one or more phosphatidylserine, one or more lysophospholipids, one or more phosphatidylethanolamine, one or more sphingomyelins, one or more dihydrophingomyelins, one or more glycerophospholipids, phosphatidylglycerol, or any combination of any two or more of these.

Description

Compositions comprising polar lipids for maintaining or increasing mobility and vitality The present invention relates to the use of polar lipids, in particular, polar lipids derived from milk, for maintaining or increasing performance and vitality. A method of using polar lipids and compositions comprising polar lipids is also provided. The progressive decline in muscle mass, strength, function, and power begins around age 40 to 45 and accelerates in old age (Doherty. J Appl Physiol(1985). 2003 Oct;95(4):1717-27; Janssen et al. J Appl Physiol(1985). 2000 Jul;89(1):81-8; Lindle et al. J Appl Physiol(1985). 1997 Nov;83(5):1581-7). Clinically, age-related muscle loss is important because it is associated with impaired mobility and vitality, and with an increased risk of falls, fractures, and other common chronic metabolic diseases (Fielding et al., J Am Med Dir Assoc. 2011 May;12(4):24956; Cruz-Jentoft et al., Age Ageing. 2018 Oct 12). Current consensus guidelines and expert opinions recommend regular exercise, particularly progressive resistance training (PRT), and adequate food and vitamin intake. Currently, there are no pharmaceutical agents available to prevent muscle loss or functional decline. Methods and compositions are required to maintain or increase operability and vitality. Accordingly, in a first embodiment, the present invention provides a method for maintaining or increasing activity and/or vitality in a subject, said method comprising the step of administering to the subject a composition comprising one or more polar lipids. Although various routes and methods of administration are considered, oral administration of polar lipids, such as compositions suitable for oral administration, is currently preferred. Of course, it will be understood that other routes and methods of administration may be used or preferred in specific situations. The term "oral administration" includes oral, buccal, intestinal, and gastric administration. The term "parenteral administration" includes, but is not limited to, topical (including administration to any dermal, epidermal, or mucosal surface), subcutaneous, intravenous, intraperitoneal, and intramuscular administration. Unless otherwise indicated, when an amount is stated as a weight percentage (%) or w/w, it should be understood that the amount represents a weight percentage or w/w on a dry matter basis. "Object" refers to mammals, such as vertebrates like humans. As used herein, the term "and/or" means "and" or "or", or both. As used herein, "(s)" following a noun refers to the plural and/or singular forms of the noun. The term "treat" and its derivatives must be interpreted in the broadest possible context. This term must not be used to mean that the subject receives treatment until complete recovery. Accordingly, "treat" broadly includes the improvement and/or prevention of the onset or severity of symptoms of a specific pathological condition. As used herein, the term “therapeutic” and grammatical synonyms refer to treatment, use, or administration in the presence of symptoms of reduced motor function and/or vitality, e.g., symptoms of sarcopenia or reduced physical performance (e.g., reduced muscle mass, strength, function, and/or strength) or net bone loss or symptoms thereof (e.g., fractures, reduced bone mineral content). As used herein, the term "preventive" and its grammatical synonyms shall be understood as considering treatment, use, administration, etc., before symptoms become apparent. Treatment will be understood to include preventive treatment of subjects, such as middle-aged or elderly subjects (e.g., subjects aged about 35 to about 95 years), or subjects with a sedentary lifestyle, including subjects for whom an increased risk of reduced mobility and/or vitality is expected or confirmed. It will be further understood that treatment includes therapeutic treatment such as the treatment of one or more sequelae associated with reduced mobility or vitality, including, for example, symptoms of sarcopenia, net bone loss, and/or reduced muscle strength or force. 1. Polar lipids and methods for obtaining polar lipids Polar lipids are generally of food grade or higher quality (e.g., generally considered safe (GRAS) and/or pharmaceutical grade). In various embodiments, one or more polar lipids for use in the present invention may be derived from milk fat. Milk fat is comprehensively discussed in the literature incorporated herein by reference [Fox and McSweeney eds, Advanced Dairy Chemistry, Volume 2 - Lipids, 3rd Ed, Springer Science + Business Media, Inc., 2006]. In addition to lipids, milk fat contains vitamins, sterols, and trace components. For a description of naturally occurring bovine milk fat, refer to the literature [Chapter 1, Composition and Structure of Bovine Milk Lipids, Fox and McSweeney]. All fractionation of milk fat is described in the literature incorporated herein by reference [Bylund, (Ed.) Dairy processing handbook. 1995 Tetra Pak